Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index

Can the Breast Cancer Index (BCI) aid selection of adjuvant oral endocrine therapy used with ovarian function suppression (OFS) for premenopausal patients?In this prognostic study of 1782 patients from a clinical trial, patients with tumors in which the expression of relative to was low (BCI [H/I]–low) derived an absolute benefit of 6.6% in 12-year breast cancer–free interval from exemestane plus OFS vs tamoxifen plus OFS and those with BCI (H/I)–high tumors had a 6.3% absolute benefit, but with variable relative treatment effects across clinical subgroups and over time. BCI was reconfirmed to be prognostic in the study population.These findings suggest that BCI may support personalized adjuvant endocrine therapy selection for some premenopausal patients with hormone receptor–positive breast cancer.

Corresponding Author: Meredith M. Regan, ScD, IBCSG Statistical Center, Division of Biostatistics, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215 (mregan@jimmy.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.